Arabic Arabic English English French French German German
dark

Rubius Therapeutics Announces Publication of RTX-240 Preclinical Data in Cancer Immunology, Immunotherapy

Rubius Therapeutics, Inc. today announced the publication of preclinical data in the peer-reviewed journal Cancer Immunology, Immunotherapy , for its lead clinical oncology program, RTX-240, for the treatment of adults with advanced solid tumors and relapsed/refractory acute myeloid leukemia. Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

White House Enlists Social Media Giants to Suppress Vaccine ‘Misinformation’

Next Post

Lexaria Completes Successful Antiviral Drug Molecular Characterization Study With Canada’s National Research Council

Related Posts
Total
0
Share